title: Potential role of tavaborole for the treatment of onychomycosis.
abstract: Systemic antifungal treatments are believed to be more effective than topicals for the treatment of onychomycosis; however, they are associated with more risks of adverse events. Tavaborole is the first member of a new class of antifungals that has been developed as a new topical nail solution for the treatment of toenail onychomycosis caused by dermatophytes. During Phase I-III clinical trials, tavaborole 5.0% nail solution showed a favorable safety and efficacy profile. Tavaborole 5.0% received US FDA market approval on 8 July 2014.
authors.affiliation: Department of Medicine, University of Toronto, ON, Canada.
authors.forename: Aditya K
authors.initials: AK
authors.lastname: Gupta
authors.forename: Deanne
authors.initials: D
authors.lastname: Daigle
mesh_terms: D000935:Antifungal Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001896:Boron Compounds / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D005533:Foot Dermatoses / Q000188:drug therapy*; D006801:Humans; D008826:Microbial Sensitivity Tests; D014009:Onychomycosis / Q000188:drug therapy*
chemical_list: D000935:Antifungal Agents; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; C512998:tavaborole
keywords: antifungal; benzoxaborole; dermatophytes; onychomycosis; toenail; topical